Measuring immune cell levels in blood after a stem cell transplant from a donor
Measures iNKT cell levels in adults after donor stem cell transplant.
Plain-language title generated from the registry record
Registry title: Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
Key facts
- Where
- Pilsen, CzechiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukaemia (AML) in complete remission who are having a stem cell transplant from a donor. Blood samples are used to count iNKT cells.
- Age
- From 18 Years to 70 Years
- Sex
- All sexes can join.
- Disease stage
- AML (secondary disease is excluded), in complete remission at the time of the stem cell transplant. Karnofsky performance status of 80% or higher.
- Earlier treatment
- The stem cells must come from the donor's peripheral blood (PBSC). No earlier transplant.
Main reasons for not taking part
- Earlier transplant
- Uncontrolled malignancy
- Secondary AML
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07570407, who can take part
Where in Czechia
- University Hospital PilsenPilsen, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Pilsen
- Trial code
- NCT07570407
- Record updated
- 13 August 2026
- Original description
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.Read full original descriptionShow less
Standardised Quantification of Invariant NKT Cells Using DryTube Technology and Flow Cytometry in Patients Who Have Undergone Allogeneic Haematopoietic Stem Cell Transplantation.
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.
Inclusion: Diagnosis: AML (exlusion of secondary disease); Disease status at time of HSCT: complete remission; Karnofsky performance status: ≥80%; Source of HSC: PBSC.
Exclusion: Prior transplant; Uncontrolled Malignancy.